This site is under development. For the current active site, go to bcbhub.csic.es.

Orcid Publication

Detalle de: NLRP3 Inflammasome Inhibition by MCC950 in Aged Mice Improves Health via Enhanced Autophagy and PPARα Activity

Title NLRP3 Inflammasome Inhibition by MCC950 in Aged Mice Improves Health via Enhanced Autophagy and PPARα Activity
Abstract

The NLRP3 inflammasome has emerged as an important regulator of metabolic disorders and age-related diseases in NLRP3-deficient mice. In this article, we determine whether, in old mice C57BL6J, the NLRP3 inflammasome inhibitor MCC950 is able to attenuate age-related metabolic syndrome to providing health benefits. We report that MCC950 attenuates metabolic and hepatic dysfunction in aged mice. In addition, MCC950 inhibited the Pi3K/AKT/mTOR pathway, enhanced autophagy, and activated peroxisome proliferator-activated receptor-α in vivo and in vitro. The data suggest that MCC950 mediates the protective effects by the mammalian target of rapamycin inhibition, thus activating autophagy and peroxisome proliferator-activated receptor-α. In conclusion, pharmacological inhibition of NLRP3 in aged mice has a significant impact on health. Thus, NLRP3 may be a therapeutic target of human age-related metabolic syndrome.

Apa Reference Marín-Aguilar, F., Castejón-Vega, B., Alcocer-Gómez, E., Lendines-Cordero, D., Cooper, M.A., de la Cruz, P., Andújar-Pulido, E., Pérez-Alegre, M., Muntané, J., Pérez-Pulido, A.J., Ryffel, B., Robertson, A.A.B., Ruiz-Cabello, J., Bullón, P. & Cordero, M.D. (2019). NLRP3 Inflammasome Inhibition by MCC950 in Aged Mice Improves Health via Enhanced Autophagy and PPARα Activity. The Journals of Gerontology: Series A, 75(8), 1457-1464. 10.1093/gerona/glz239
Doi 10.1093/gerona/glz239
Publication Date 11 Oct 2019
Publication Type Article
Researcher M Eloísa Andújar Pulido
Ontology Drug Discovery and design
Research Groups
Tools

Suggest changes

Publications are synced automatically from ORCID, so they can't be edited here directly. Spotted something wrong? Let us know below and we'll take care of it.

← Return to Home